Drugs Information:
Bazedoxifene
Basic Information
|
||
ID | DDInter167 | |
Drug Type | small molecule | |
Molecular Formula | C30H34N2O3 | |
Molecular Weight | 470.613 | |
CAS Number | 198481-32-2 | |
Description | Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause, as well as the prevention of postmenopausal osteoporosis in women. | |
ATC Classification | G03XC02 G03CC07 | |
IUPAC Name | 1-({4-[2-(azepan-1-yl)ethoxy]phenyl}methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol | |
InChI | UCJGJABZCDBEDK-UHFFFAOYSA-N | |
Canonical SMILES | CC1=C(N(CC2=CC=C(OCCN3CCCCCC3)C=C2)C2=C1C=C(O)C=C2)C1=CC=C(O)C=C1 | |
Useful Links | DrugBank ChEBI PubChem Substance KEGG Drug ChemSpider BindingDB Wikipedia ChEMBL ZINC |
Interactions with
Bazedoxifene
Filter:
Severity level | ID | Name | Mechanism | Detail |
---|
Interactions with diseases
Filter:
Severity level | Disease name | Text | References |
---|
Interactions with foods
Filter:
Severity level | Food name | Description | Management | Mechanism | References |
---|
Interactions with compound preparation
Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
---|